Replimune Group, Inc. (REPL)
7.61
-0.04
(-0.52%)
USD |
NASDAQ |
Apr 01, 16:00
7.62
+0.01
(+0.13%)
After-Hours: 20:00
Replimune Group Research and Development Expense (TTM) : 222.70M for Dec. 31, 2025
Research and Development Expense (TTM) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (TTM) Benchmarks
| ANI Pharmaceuticals, Inc. | 51.66M |
| Phathom Pharmaceuticals, Inc. | 32.78M |
| REGENXBIO, Inc. | 212.68M |
| Corcept Therapeutics, Inc. | 254.91M |
| Catalyst Pharmaceuticals, Inc. | 12.71M |